ExpreS2ion´s new joint venture, AdaptVac, reaches proof of concept in animals for breakthrough breast cancer vaccine treatment
(WorldNews Denmark)

Hørsholm, Denmark, October 18, 2017 - Today, ExpreS2ion Biotech Holding AB (`ExpreS2ion`) announces that its joint venture, AdaptVac ApS (`AdaptVac`), has reached proof of concept in advanced animal models (POCA) for AV-001, its novel vaccine treatment against breast cancer tumours. This is a significant milestone for AdaptVac in the progress towards clinical development. AdaptVac will now initiate discussions with large pharmaceutical companies regarding a license or collaboration agreement for the clinical development of the project. The scientific results that form the basis of the proof of concept in animal models show a strong therapeutic effect on par with leading treatments on the...